Table 1. Patient characteristics (n = 21).
| Characteristic | n (%) |
|---|---|
| Median age, years (Range) | 55 (46–71) |
| FIGO Stage | |
| • I | 1 (4.8) |
| • II | 1 (4.8) |
| • III | 15 (71.4) |
| • IV | 4 (19.0) |
| Histology | |
| • Serous | 20 (95.2) |
| • Clear cell | 1 (4.8) |
| Site | |
| • Ovarian | 20 (95.2) |
| • Fallopian tube | 1 (4.8) |
| Genetic testing | |
| • BRCA1 | 1 (4.8) |
| • BRCA2 | 2 (9.5) |
| • BRIP1 | 1 (4.8) |
| • Negative/Unknown | 17 (80.9) |
| Treatment at primary diagnosis | |
| • Neoadjuvant chemotherapy/interval cytoreduction | 10 (47.6) |
| • Initial cytoreduction/adjuvant chemotherapy | 11 (52.3) |
| Recurrence history | |
| • Platinum sensitive, then platinum resistant | 9 (42.8) |
| • Platinum resistant at initial recurrence | 12 (57.1) |
| Number of previous lines of therapy | |
| • 1 | 2 (9.5) |
| • 2 | 11 (52.3) |
| • 3 | 6 (28.5) |
| • 4 | 1 (4.8) |
| • 5 | 1 (4.8) |
| Prior targeted therapy | |
| • Bevacizumab | 10 (47.6) |
| • PARP inhibitor | 4 (19.0) |